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Abstract
Background: Medicare covers several cancer screening tests not currently recommended by the U.S. Preventive
Services Task Force (Task Force). In September 2002, the Task Force relaxed the upper age limit of 70 years for
breast cancer screening recommendations, and in March 2003 an upper age limit of 65 years was introduced for
cervical cancer screening recommendations. We assessed whether mammogram and Pap test utilization among
women with Medicare coverage is influenced by changes in the Task Force’s recommendations for screening.
Methods: We identified female Medicare beneficiaries aged 66–80 years and used bivariate probit regression to
examine the receipt of breast (mammogram) and cervical (Pap test) cancer screening reflecting changes in the
Task Force recommendations. We analyzed 9,760 Medicare Current Beneficiary Survey responses from 2001
to 2007.
Results: More than two-thirds reported receiving a mammogram and more than one-third a Pap test in the
previous 2 years. Lack of recommendation was given as a reason for not getting screened among the majority
(51% for mammogram and 75% for Pap). After controlling for beneficiary-level socioeconomic characteristics
and access to care factors, we did not observe a significant change in breast and cervical cancer screening
patterns following the changes in Task Force recommendations.
Conclusions: Although there is evidence that many Medicare beneficiaries adhere to screening guidelines, some
women may be receiving non-recommended screening services covered by Medicare.
Introduction
Medicare, the largest payer for health care services inthe United States, covers many preventive services in-
cluding cancer screening. To make these decisions, Medicare
may be influenced by the recommendations of the United
States Preventive Services Task Force (hereafter, ‘‘Task
Force’’). The Task Force, an independent panel of experts,
develops recommendations for optimal delivery of preven-
tive services including cancer screening frequency. The Cen-
ters for Medicare and Medicaid Services is now authorized to
cover preventive services given certain statutory require-
ments, one of which is receiving a grade A (strongly recom-
mends) or grade B (recommends) rating from the Task Force.1
During the past 20 years, Medicare’s coverage of breast and
cervical cancer screening has changed, and it has not always
been concordant with Task Force recommendations.2,3
Medicare covers screening tests for both breast and cervical
cancers for all female beneficiaries regardless of age, whereas
the Task Force recommendations have often included upper
age limits on who should get screened.4,5 For instance from
1996–2002, the Task Force recommended screening women
ages 50–69 years old for breast cancer (‘‘A’’ rating), but gave
an ‘‘I’’ rating for screening women ages 70 years and older,
concluding that there insufficient evidence to assess the bal-
ance of benefits and harms of the test. However, between 2002
and 2009, the Task Force changed its recommendation and
suggested that women ages 40 and older get a mammogram
every 1–2 years6 (‘‘B’’ rating) and provided no upper limit
for screening. Similarly, since 1996, the Task Force has re-
commended cervical cancer screening for women ages 21
through 65 once every 3 years but has made a distinction for
women over age 65. Initially, it cited insufficient evidence in
this age group. However, an age ceiling was added to the
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recommendation in September 2003, suggesting the vast
majority of female Medicare beneficiaries should not get Pap
tests if they were to follow Task Force recommendations.
Meanwhile, some advocacy groups encourage screening for
women over 70 and not previously screened or for whom
information about previous screening is unavailable.7,8
A timeline summarizing Medicare coverage of breast and
cervical cancer screening and the corresponding Task Force
recommendations is presented in Fig. 1. Medicare first cov-
ered these screening tests in the early 1990s and since then has
gradually removed cost-sharing requirements for its benefi-
ciaries. The timeline also highlights Medicare’s coverage of
wellness-related visits as screening services may be offered
during these visits. In 2005, Medicare introduced two types of
wellness visits in line with findings suggesting that periodic
health exams may be associated with a higher likelihood of
receiving recommended preventive services, including cancer
screening.9,10 Although persistent barriers to preventive visits
and cancer screening have kept screening rates from reaching
optimal levels,11 improved financial access to preventive
services may leave Medicare beneficiaries susceptible to in-
appropriate use of mammograms and Pap tests, particularly
when Task Force recommendations indicate to stop screening
at older ages.
Unfortunately, the effects of changing stopping ages for
screening have not been well studied. Cancer screening uti-
lization has been examined in relation to predictors of pre-
ventive care in various U.S. populations12–16 with studies
showing that younger age, education, income, urban resi-
dence, having a usual source of healthcare, and physician
recommendation positively influence screening behav-
ior.13,16,17 However, recent reports have also shown a small
FIG. 1. Breast and cervical cancer screening: Medicare coverage and United States Preventive services Task Force (USPSTF)
recommendations. USPSTF Recommendation grades:
A: There is a high level of certainty that net benefit is substantial. Prior to May, 2007, the definition for grade A was the
following: ‘‘The USPSTF strongly recommend that clinicians provide [the service] to eligible patients. The USPSTF
found good evidence that [the service] improves important health outcomes and concludes that benefits substantially
outweigh harms.’’
B: There is high certainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to
substantial. Prior to May 2007, the definition for grade B was the following: ‘‘The USPSTF recommends that clinicians
provide [the service] to eligible patients. The USPSTF found at least fair evidence that [the service] improves important
health outcomes and concludes the benefits outweigh harms.’’
D: There is moderate or high certainty that the service has no benefit or that the harms outweigh the benefits.
I: The current evidence is insufficient to assess the balance of benefits and harms of the service.
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decline in receipt of mammograms among women 40 or older
between 2000 and 2005 as well as a slight decrease in Pap
testing during the same years.16,18,19 The reasons for this are
unclear but may be related to changing recommendations. A
recent survey of primary care physicians (PCPs) found that
the influence of screening guidelines varies by specialty (i.e.,
family practice, internal medicine, or OB/GYN), by the per-
ceived aggressiveness of the recommendations, and by the
number and agreement of different guideline recommenda-
tions.20 Among the physicians surveyed, Task Force recom-
mendations were found to be less influential than those issued
by the American Cancer Society (ACS) or the American Col-
lege of Obstetricians and Gynecologists (ACOG).
Our objective was to build upon this knowledge by testing
whether changes in Task Force recommendations (i.e., relaxing
the upper age limit of 70 years for mammograms in 2002 and
introducing an upper age limit for Pap tests in 2003) were as-
sociated with rates of cancer screening among female Medicare
beneficiaries surveyed with the Medicare Current Beneficiary
Survey (MCBS). We expect that the change in recommendations
for cervical cancer screening would produce a more significant
effect on screening rates than changes in breast cancer screening
recommendations, given that the cervical cancer recommen-
dations moved to a definitive no screen recommendation
(whereas breast recommendations moved from a recommen-
dation for screening to a statement of insufficient evidence).
Materials and Methods
The conceptual model for this study is based on Andersen’s
health behavior model,21 which suggests that patient, pro-
vider, and insurance plan characteristics all influence cancer
screening utilization.12 Prior studies have shown that most
mammograms and Pap tests occur only after a referral from a
physician.22–25 As providers implement updated recommen-
dations, we expect that screening patterns would reflect
changes in screening recommendations.
Data sources
Data were obtained from the 2001–2007 waves of the MCBS
and thus provide screening rates for the year or two preceding
the changed Task Force guidelines and several years after-
ward. The MCBS has been administered annually to a na-
tionally representative sample of the Medicare population
since 1991. Each year, the MCBS gathers data from approxi-
mately 16,000 Medicare enrollees on topics including health
status, health insurance coverage and financing, access to
care, knowledge, and understanding Medicare, as well as use
and effectiveness of new program benefits and changes. The
detailed sampling scheme and methods for data collection are
described elsewhere.26,27 Several prior studies have used the
MCBS to examine cancer screening patterns and use of other
preventive services within the Medicare population.28–31
We restricted our analyses to female, community-dwelling
MCBS respondents aged 66–80 years at the time they were
interviewed. We excluded beneficiaries with a history of end
stage renal disease who may have enrolled in Medicare prior
to age 65. Women with a history of breast or cervical cancer
were excluded. We excluded women who reported having a
mastectomy but chose to include women who reported a
hysterectomy because studies have shown that Pap testing
occurs among this group.16
Dependent variables
We developed two self-reported measures to assess annual
receipt of mammograms and Pap tests. The MCBS asks
Medicare beneficiaries whether they have ‘‘had a mammo-
gram or breast X-ray’’ and whether they have ‘‘had a Pap
smear test’’ in the prior year. We combined responses for
every 2 consecutive years to develop biennial screening out-
comes; the women could indicate ‘‘yes’’ in either year ob-
served. We chose this measure because it was consistent with
the frequency for mammogram testing in the Task Force
recommendations. The choice to observe biennial Pap testing
was more arbitrary, but it was mainly to parallel the obser-
vation interval for mammogram testing; the Task Force re-
commended Pap testing frequency ranged between once
every 1–3 years prior to 2003 to once every 3 years starting in
2003. Women who reported not getting a mammogram or Pap
test were asked additional questions about their reasons for
not getting screened. We were interested in those explana-
tions related to screening recommendations, particularly that
the test wasn’t needed or was not recommended annually, a
doctor did not prescribe or recommend it, the patient had a
mastectomy (or hysterectomy), and not being at risk for breast
(or cervical) cancer.’’
Independent variables
Our model included variables to control for many predis-
posing and enabling factors and service needs. Because the
Task Force updates for breast and cervical cancer screening
were within 5 months of each other but in different calendar
years, we were interested in an indicator variable for the Task
Force recommendation change that flagged survey time pe-
riods 2003–2004 and later. We allowed a 1-year lag from the
actual date the recommendation change occurred, because the
MCBS asked about the previous year’s health utilization.
Even though we previously showed that the Welcome to
Medicare visit had no effect on screening patterns in this
population,31 we created a flag to control for the time when
Medicare introduced this benefit (2005–2006 and later). We
were also interested in enrollees’ place of residence (metro-
politan area), demographic (age, race, and ethnicity) and so-
cioeconomic characteristics (income, high school graduation,
and marital status), self-rated overall health (excellent, very
good, good, fair, or poor), and personal history of cancer. We
modeled age as a continuous variable; all other variables were
categorical. Type of health insurance coverage was catego-
rized into four mutually exclusive groups: Medicare Parts
A + B only (Medicare-only), Medicare Advantage, Medicare
plus Medicaid (Medicare-Medicaid), and Medicare Parts
A + B with supplemental insurance (either employer-spon-
sored or self-purchased insurance). We included an indicator
of having a usual source of primary care to control for access
to health care.
Statistical analyses
We used Pearson chi-square tests to examine differences in
receipt of mammograms and Pap tests by time period (pre/
post 2003–2004) and in the reasons women cited for not get-
ting screened. We estimated equations that described cancer
screening among women using bivariate probit regression.
This allowed us to model both screening tests simultaneously
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using pooled analysis to estimate receipt of screening among
women enrolled in Medicare between 2001 and 2007. We
tested the independence of the separate mammogram and
Pap test equations with a Wald test and rejected the hypoth-
esis that r = 0. Because beneficiaries had multiple survey re-
sponses across years, we performed clustered analyses at the
individual level and used Huber-White robust standard er-
rors. After estimating the bivariate probit model for the full
sample, we then estimated separate models for women
younger than 70 years and those older than 70, because this
was the stopping age for the Task Force mammogram rec-
ommendations at the beginning of our observation period6
(results not shown). We tested the sensitivity of using annual
versus biennial screening rates. All models accounted for the
complex MCBS survey design by using cross-sectional survey




The descriptive statistics in Table 1 pertain to the pooled
sample, and thus the sample size reflects 9,760 observations of
person-years rather than persons. Women who met our in-
clusion criteria and participated in the MCBS for 2 or more
consecutive years were mostly white women (78.0%) living in
metropolitan areas (76.7%). The mean age at time of survey
was 73.5 years. In terms of insurance coverage, 31.1% had
Medicare Parts A + B only, 8.2% were enrolled in Medicare
Advantage plans, 13.2% were dually eligible for Medicaid,
and 47.5% had Medicare Parts A + B with supplementary in-
surance. Approximately 79% reported having a usual source
of primary care, and 80% reported a self-perceived health
status between good and excellent.
Cancer screening and reasons for not getting screened
Table 2 displays the self-reported prevalence of cancer
screening and reasons for not getting screened stratified by
screening test and time period. We chose to report biennial
rates; the biennial mammogram rate was 75.6% for women
under 70 and slightly lower (69.6%) for women over 70 (re-
sults not shown). We did not observe a statistically significant
change in mammogram rates for women after the Task Force
issued its 2002 recommendations, which recommended
screening for all women older than 40 years and provided no
stopping age (70.6% before Task Force changes vs. 71.5% af-
ter). Approximately half of women who did not receive
mammograms said the reason was related to screening not
being recommended. There was a significant decline in those
agreeing that a mammogram was not needed (28.6% before
the Task Force change and 23.0% after).
Despite the 2003 Task Force recommendations to stop
cervical cancer screening after age 65, we did not see a decline
in biennial Pap test rates until after 2005 (34.3% after 2005 vs.
37.1% immediately following the change). Among women
older than 65 who did not receive Pap tests, approximately
75% reported that screening was not recommended. Of the
women who received recommendations not to screen, there
was a significant decline in those agreeing that the test was not
needed from 23.0% before to 19.4% after the change in rec-
ommendations.
Regression results
Table 3 presents the multivariate regression results simul-
taneously examining the receipt of the two tests. There was no
significant association between receipt of cancer screening
and the time period immediately following the updated Task
Force recommendations (2003–2004 to 2004–2005). However,
we observed that women were less likely to receive a Pap test
between 2005–2006 and 2006–2007 ( p = 0.03). On average
women who were married, had a usual place of primary care,
and resided in a metropolitan area were more likely to receive
mammogram and Pap testing. Women were less likely to
receive cancer screening if they had less than a high school
education, had a household income below $25,000, and re-
ported being in fair to poor health. In addition, women with a
history of non-skin cancer and those with supplemental
Table 1. Sample Characteristics
of Female MCBS Respondents
Variable Percent
Predisposing characteristics










History of non-skin cancer 10.8
Hysterectomy 35.1
Less than high school 26.4
Household income < $25,000 56.5
Enabling characteristics
Medicare insurance type
Medicare parts A–B only 31.1
Medicare Advantage 8.2
Medicare + Medicaid 13.2
Medicare + supplemental insurance 47.5
Usual place of medical care and physician
Primary care 79.1
Non-primary care 17.0
No usual place of care 3.9
















MCBS, Medicare Current Beneficiary Survey; SD, standard devi-
ation.
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insurance coverage were more likely to receive a mammo-
gram. Compared with women with only Medicare A + B
coverage, women with Medicare Advantage and those with
dual coverage were less likely to receive a mammogram
but this had no significant effect on Pap testing. Overall, we
observed a weak inverse relationship between age and receipt
of screening for both tests. Being in fair to poor health was
associated with lower likelihood of mammogram and
Pap testing. Black beneficiaries were more likely to receive
mammogram and Pap testing compared to white women.
Additionally, Hispanic women were more likely to receive
cervical cancer screening compared with their non-Hispanic
counterparts.
Discussion
This study found that more than two-thirds of female
MCBS respondents older than 65 years of age reported re-
ceiving a mammogram and more than one-third reported
getting a Pap test in the 2-year period preceding the survey.
These rates are in line with national estimates of cancer
screening32 and did not appear to be significantly affected by
changes in Task Force recommendations for either cervical
cancer screening or breast cancer screening, at least during the
period of study. The only exception is the drop in Pap test
rates during 2005–2006 to 2006–2007, which may be partially
explained by a lagged response to the 2003 Task Force change.
Furthermore, for those who were not screened, there did not
appear to be an appreciable increase in knowledge that
screening is not needed or an appreciable increase in doctor
recommendations against screening.
Although we did not observe immediate responses in the
proportion of women screened between 2001 and 2007 after
the changes in screening recommendations, this was perhaps
not surprising. While the recommended stopping age of
65 years was reintroduced for Pap tests in 2003, Medicare
coverage for preventive services has become more generous,
leading to the elimination of cost sharing requirements.
Meanwhile, ACOG and ACS, two organizations viewed
to be more influential by PCPs when it comes to screening
decisions,20 did not introduce an age ceiling to their recom-
mendations. Thus, both patients and doctors are receiving
conflicting signals regarding the benefits of cervical cancer
screening. In settings where such conflicting signals are ab-
sent, women appear to have responded to changing recom-
mendations for cervical cancer screening.10,19 Further, the
Table 2. Self-Reported Biennial Mammogram and Pap Test Rates and Reasons
for Not Getting Screened, Among Female MCBS Respondents
Mammogram Pap test
Time period < 2003–2004 ‡ 2003–2004 All < 2003–2004 ‡ 2003–2004 All
Total female responses, N 3,500 6,260 9,760 3,500 6,260 9,760
Had screening in this time period 71.2 70.6 70.8 35.7 35.7 35.7
Among those who answered ‘‘No’’ N{ 1,009 1,840 2,849 2,245 4,040 6,285
Reason for not getting screened:
Not recommended{ 51.5 51.0 51.2 75.0 75.1 75.1
Wasn’t needed/no need/nothing wrong 28.6 25.4* 26.5 23.0 19.9* 21.0
Not recommended annually/different schedule 8.6 10.7 10.0 14.2 15.4 15.0
Doctor did not prescribe or recommend it 14.6 15.8 15.4 22.3 22.3 22.3
Doctor recommended against getting it 0.7 0.5 0.6 1.4 1.6 1.6
Had a mastectomy (hysterectomy) 1.0 0.7 0.8 18.5 22.1* 20.9
Not at risk for breast (cervical) cancer 2.3 2.3 2.3 1.2 1.0 1.1
*Significant difference at P < 0.05.
{Due to sample weighting, dividing the number of those who answered ‘‘No’’ by the total number of female responses does not result in the
exact complement of the percent screened.
{Reasons given are not mutually exclusive and the sum of percentages exceeds % not recommended.
Table 3. Bivariate Probit Model: Factors
Associated with Cancer Screening
Among Female MCBS Respondents, Ages 66–80 Years
Mammogram Pap test
Characteristics b SE b SE
Predisposing characteristics
Time period ‡ 2003–2004{ - 0.02 0.03 - 0.03 0.03
Age - 0.02** 0.00 - 0.02** 0.00
Black 0.22** 0.05 0.27** 0.05
Hispanic - 0.04 0.05 0.16** 0.05
Married 0.16** 0.03 0.08* 0.03
History of non-skin cancer 0.09* 0.05 0.05 0.04
Hysterectomy 0.11** 0.03 - 0.07** 0.03
Less than high school - 0.17** 0.04 - 0.13** 0.04
Household income < $25,000 - 0.19** 0.03 - 0.17** 0.03
Enabling characteristics
Medicare Advantage - 0.13* 0.06 - 0.02 0.05
Medicare + Medicaid - 0.10* 0.04 0.02 0.05
Medicare + supplemental
insurance
0.08* 0.03 0.01 0.03
Primary care as usual
place of care
0.24** 0.03 0.17** 0.03
Residing in a metropolitan
area
0.11** 0.03 0.10** 0.03
Need characteristics
Fair to poor health - 0.23** 0.04 - 0.16** 0.04
Intercept 2.16** 0.27 1.34** 0.26
rMP{ 0.65**
*,**Significantly different from 0 at a = 0.05, and 0.01 level,
respectively.
{U.S. Preventive Services Task Force removed the stopping age for
mammography in late 2002 and again reintroduced the age limit of
65 years for Pap tests in early 2003.
{The correlation of UM and UP.
SE, Huber-White robust standard error.
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change in breast cancer screening recommendations sent a
murkier signal for changing screening behavior. The ‘‘I’’ rat-
ing between 1996 and 2002 meant that there was insufficient
evidence to determine the balance of benefits and harms for
screening. Meanwhile, women and their doctors had likely
been screening for breast cancer for years (between age 50 and
69) and may have elected to continue screening into older age
based on presumed benefit. Such behavior would make the
2002 change to a ‘‘B’’ recommendation, fair evidence that
benefits outweigh harms, a less potent motivator of significant
changes in behavior. We are unable to tease out the complex
interplay of such factors in this sample. Many older adults
may view screening cessation as a major decision. On the
other hand, continued screening may be viewed as a habit or
custom not involving any decision.33
Underuse
Despite increased access to preventive services, 22.4% of
women under 70 and 30.4% aged 70–80 years did not report
getting a mammogram in the past 2 years. This suggests that
although the age ceiling was removed for mammograms,
many women did not take advantage of the covered service.
Even though Medicare attempts to minimize access barriers
associated with financial resources, each patient and her
doctor must weigh the benefits and harms of screening. There
may be a number of other reasons women do not get screened,
including a shorter life expectancy, more serious comorbid-
ities, or individual patient preference. A recent analysis of
Medicare data found that people who experience serious
health events like hospitalization or heart attacks may choose
to suspend or discontinue screening.34
Overuse
The finding that approximately one-third of women over
age 65 reported getting cervical screening suggests unneces-
sary testing and the potential for detection of indolent lesions.
Further, Pap tests and subsequent follow-up procedures will
entail additional expenditures that may cause more harm
than benefit. The decision to stop screening is a complicated
one that requires women understand personal risk.33 There-
fore, as life expectancy in the U.S. increases, we will need
additional studies on screening in elderly populations to
inform better age-specific updates. Provider-patient commu-
nication regarding screening is paramount, especially in fo-
cusing on patient-centered care. Attention to individual
patient considerations is evident in the Task Force recom-
mendations, which advise patients and clinicians to make
decisions after weighing all the benefits and harms.
Limitations and conclusions
Even though these findings do not demonstrate a causal
relationship between Task Force changes and adherence to
recommendations, they do provide insight into trends and
persistently poor screening rates. This study was based on
self-reported screening and is subject to recall bias. However,
previous studies support reasonable validity of self-reported
cancer screening,35 and it is unlikely that any potential mis-
classification would be correlated with the change in Task
Force recommendations. Because we examined only two
cancer screening tests, our findings may not apply to other
preventives services including other cancer screening tests.
We also recognize that the Task Force recommendations have
changed again since the study period, but the underlying
drivers for screening behavior have not changed. Screening
decisions are complex and are influenced by patient predis-
posing, enabling, and need-based factors in addition to other
patient–provider interactions. Future studies should examine
these multilevel relationships.
In conclusion, Medicare populations do not exhibit changes
in screening behavior based on changing Task Force recom-
mendations. Although the reasons for this are complex and
multifactorial, it is likely at least in part due to misalignment
of financial incentives and recommendations and lack of ap-
propriate physician and patient education about when to stop
screening. Although additional screening coverage is gener-
ally encouraged because it aims to increase access to services
for vulnerable populations, Medicare policies should be
careful not to promote inappropriate use of screening.36 Pro-
moting conversations between clinicians and patients about
age-appropriate screening may represent a valuable oppor-
tunity to address both overuse and underuse of certain tests
among Medicare beneficiaries. Increased alignment of bene-
fits covered by Medicare and recommendations from the
Task Force is likely to increase appropriate screening.2,3,36,37
This study highlights an opportunity to improve health care
quality among a group of patients who sometimes receive
conflicting messages about cancer prevention.
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